A Baylor College of Medicine-led team has developed a strategy that combines the analysis of thousands of proteins with artificial intelligence (AI) to accelerate the discovery of small molecules called ‘molecular glues’ to treat disease. Their novel approach has uncovered a new class of molecular glues that can potentially neutralize harmful proteins that have been linked to blood cancers and autoimmune diseases. The work also shows how AI-based structural modeling can guide chemists early for compound optimization, well before experiments reveal how a compound works.

At a dedicated press conference at the EASD Annual Meeting in Milan, organised by the European Diabetes Forum (EUDF), three leading European cardiometabolic scientific associations - the European Society of Cardiology (ESC), the European Association for the Study of Diabetes (EASD) and the European Association for the Study of Obesity (EASO) - joined European Commissioner for Health and Animal Welfare Olivér Várhelyi to welcome the launch of the first-ever EU Screening Week.

Researchers at Mass General Brigham found that moderate-intensity exercise alters circulating extracellular vesicles in ways that promote cartilage health and tissue resillence, identifying microRNA-29 as a key mediator that improved characteristics of aged cartilage cells and reduced signs of joint degeneration. Published in Nature Aging, the findings provide new insight into how exercise protects joints and could inform future osteoarthritis treatments designed to reproduce exercise’s beneficial biological effects for patients who cannot exercise sufficiently.

(Boston)—Joshua D. Campbell, PhD, associate professor of medicine at Boston University Chobanian & Avedisian School of Medicine, has been awarded a five-year, $3.4M U01 grant from the NIH’s National Cancer Institute Human Tumor Atlas Network (HTAN) for the project, “Integrative biomarkers to improve clinical management of lung ground glass nodules.” Campbell and colleagues led the establishment of the Lung Pre-Cancer Atlas, a cellular map of the earliest stages of lung cancer during the first round of HTAN funding (Phase I - A. Spira). This Phase II award will allow the team to begin to translate the Lung Pre-Cancer Atlas efforts into clinically useful biomarkers.

The position statement emphasizes that lifestyle medicine's six pillars–optimal nutrition, physical activity, restorative sleep, stress management, connectedness, and avoidance of risky substances––can benefit both individual and environmental health.